Regenxbio – Chart Of The Day


Even on days when the market tanks Barchart can help you find stocks beating the trends.The Barchart Chart of the Day belongs to Regenxbio (RGNX). I found the biomedical stock by using Barchart to sort today’s  Top Stocks to Own list first by the most frequent number of new highs in the last month then I used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 4/16 gthe stock gained 85.79%.

Regenxbio Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. Regenxbio Inc. is headquartered in Rockville, Maryland.

Barchart’s Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 237.85+ Weighted Alpha
  • 221.23% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 14 new highs and up 42.36% in the last month
  • Relative Strength index 79.19%
  • Technical support level at 66.78
  • Recently traded at 69.95 with a 50 day moving average of 48.96
  • Reviews

    • Total Score 0%
    User rating: 0.00% ( 0
    votes )



    Leave a Reply

    Your email address will not be published. Required fields are marked *